Hemispherx Biopharma (HEB) 0.25 $HEB
Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
GlobeNewswire - Thu Feb 12, 7:30AM CST
Ampligen(R) May Be an Important Candidate for EBOV Testing in West Africa
HEB: 0.25 (+0.01)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo
GlobeNewswire - Mon Feb 09, 7:30AM CST
Based upon numerous Hemispherx stockholder requests, Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
has posted the report and findings of the recent efficacy study of Ampligen(R) in a mouse model of Ebola virus infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). The posted USAMRIID report conclusively refutes false and defamatory blog and online statements by TheStreet.com's blogger Adam Feuerstein and invalidates Feuerstein's negative social media postings about the company's press release that was issued on February 2, 2015.
HEB: 0.25 (+0.01)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 90.70 (+0.93), ADXS: 7.18 (+0.06), GILD: 101.90 (+1.10), HEB: 0.25 (+0.01), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You
at The Street - Wed Feb 04, 11:59AM CST
A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.
HEB: 0.25 (+0.01)
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
GlobeNewswire - Mon Feb 02, 9:05AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today the results of a new efficacy study of Ampligen(R) in a mouse model of Ebola virus (EBOV) infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID).
HEB: 0.25 (+0.01)
USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
GlobeNewswire - Mon Jan 26, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today that in a new publication in the journal mBio, scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID), Harvard University, and Massachusetts Institute of Technology (MIT) studied genetic changes in the Ebola virus (EBOV) circulating in West Africa and concluded that genomic drift of the EBOV over time may be sufficient to block the action of otherwise potential therapies that target EBOV genetic sequences. The types of potential drugs at risk include monoclonal antibodies and small-interfering RNA (siRNA) which are scheduled to be evaluated during the current outbreak (see below). The USAMRIID press release states that "genetic drift must be considered when developing potential therapeutics, in order to ensure that changes in the Ebola virus over time do not render those treatments ineffective......the USAMRIID team compared the current strain, called EBOV/Mak, with the two previous strains that caused outbreaks in 1976 and 1995 in Zaire (now the Democratic Republic of the Congo). In each comparison, they found more than 600 genetic mutations. Next, the group focused on only the mutations that occurred in the genetic sequences targeted by the experimental therapeutics. Of these, they found 10 new mutations that might interfere with the mechanisms of the sequence-based drugs currently being tested. Three of these mutations appeared during the current West African outbreak." (http://www.usamriid.army.mil/newsroom.htm).
HEB: 0.25 (+0.01)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Hemispherx Biopharma Awarded $770,852 by Federal Judge
GlobeNewswire - Thu Jan 15, 7:59AM CST
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx" announced that after prevailing in a federal lawsuit brought against the Company by Cato Capital, the United States District Court for the District of Delaware has ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76. Previously, in September 2014, the Court dismissed all claims brought by Cato against Hemispherx, including counts of breach of contract and fraudulent inducement--completely vindicating the Company of any wrongdoing.
HEB: 0.25 (+0.01)
Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
GlobeNewswire - Mon Jan 12, 8:16AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen(R) (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx.
HEB: 0.25 (+0.01)
Biotech Weekly: Lessons Learned From Investing In Ebola Stocks
Daniel Ward - at Seeking Alpha - Mon Jan 12, 7:38AM CST
HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36)
Arrowhead Issues Diligence and Valuation Report on Hemispherx Biopharma
GlobeNewswire - Fri Jan 09, 7:38AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announces that Arrowhead BID issued an analyst report on Thursday, January 8, 2015 which can be seen at http://www.abid.co/sites/default/files/HEMISP...8Jan15.pdf.
HEB: 0.25 (+0.01)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22)
Hemispherx Biopharma Down 5.3%, Shares Slide into the Red (HEB)
Comtex SmarTrend(R) - Tue Dec 23, 12:41PM CST
Hemispherx Biopharma (AMEX:HEB) is one of today's worst performing penny stocks, down 5.3% to $0.23 on 1.1x average daily volume. Thus far today, Hemispherx Biopharma has traded 847,000 shares, vs. average volume of 747,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's 0.6%) and underperformed the S&P 500 (-5.3% to the S&P's 0.3%) during today's trading.
HEB: 0.25 (+0.01)
Biotech Equities Technical Analysis -- Incyte, ZIOPHARM Oncology, Hemispherx Biopharma, Infinity Pharma, and Orexigen Therapeutics
PR Newswire - Fri Dec 19, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Hemispherx Biopharma Inc. (NYSE MKT: HEB), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 18, 2014, rallied as the Dow Jones Industrial Average finished at 17,778.15, up 2.43% and the NASDAQ Composite closed at 4,748.40, up 2.24%. The S&P 500 finished the session 2.40% higher at 2,061.23. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 813.60, up 2.77%, with the index advancing 8.37% in the previous three months. Register for your complimentary reports on these five stocks at:
OREX: 5.55 (+0.10), ZIOP: 9.64 (-0.35), HEB: 0.25 (+0.01), INCY: 75.94 (+0.28), INFI: 15.13 (+0.55)
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
GlobeNewswire - Tue Dec 16, 7:37AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today further progress on developing Ampligen(R) (rintatolimod) as a potential therapeutic complement to a new molecular class of anti-tumor drugs termed immune checkpoint inhibitors or PD-1 inhibitors (also called Programmed Death inhibitors). PD-1 inhibitors act to unleash the body's own immune system to scavenge/ destroy tumors: remarkable success to date clinically has been reported by Bristol Meyers Squibb (BMS), Merck, Genetech and Novartis on a variety of human tumors including malignant melanoma and metastatic renal cancer with PD inhibitors. In some of these cases, full regulatory approval of commercialization for PD-1 inhibitors has already been received internationally or is expected to be received shortly. Objective tumor regressions are typically seen in approximately 10 to 25% of patients with PD-1 checkpoint inhibitors, such compounds have been generally well-tolerated clinically with a few exceptions noted to date.
HEB: 0.25 (+0.01), MRK: 58.81 (-0.07)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), TKMR: 21.45 (-0.22), ABIO: 0.70 (+0.03)
Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research
GlobeNewswire - Tue Dec 09, 8:52AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today that it has received a new research report (dated December 5, 2014) from researchers at Howard University, Washington DC. The report describes a study in which Ampligen(R) (Poly I : Poly C12U) strongly inhibited the Ebola minigenome in the human embryonic kidney cell system. The Ebola minigenome replication system was recently described by the researchers in the Journal of Biological Chemistry (2014) (Role of Protein Phosphatase 1 in Dephosphorylation of Ebola Virus VP30 Protein and Its Targeting for the Inhibition of Viral Transcription; Ilinykh et al. 289(33):22723-22738). In the minigenome replication system, certain genetic information for viral proteins has been deleted from the genomic array to permit safer and more efficient laboratory manipulations.
HEB: 0.25 (+0.01)
Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 08, 10:35AM CST
HEB: 0.25 (+0.01), IBIO: 0.90 (+0.36), MNKD: 7.00 (+0.02), ARNA: 4.55 (+0.02)
Biotech industry group supports adding Ebola to Voucher Program Act
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 12:57PM CST
JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
GlobeNewswire - Thu Feb 12, 7:30AM CST
Ampligen(R) May Be an Important Candidate for EBOV Testing in West Africa
HEB: 0.25 (+0.01)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo
GlobeNewswire - Mon Feb 09, 7:30AM CST
Based upon numerous Hemispherx stockholder requests, Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
has posted the report and findings of the recent efficacy study of Ampligen(R) in a mouse model of Ebola virus infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). The posted USAMRIID report conclusively refutes false and defamatory blog and online statements by TheStreet.com's blogger Adam Feuerstein and invalidates Feuerstein's negative social media postings about the company's press release that was issued on February 2, 2015. HEB: 0.25 (+0.01)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 90.70 (+0.93), ADXS: 7.18 (+0.06), GILD: 101.90 (+1.10), HEB: 0.25 (+0.01), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You
at The Street - Wed Feb 04, 11:59AM CST
A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.
HEB: 0.25 (+0.01)
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
GlobeNewswire - Mon Feb 02, 9:05AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today the results of a new efficacy study of Ampligen(R) in a mouse model of Ebola virus (EBOV) infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). HEB: 0.25 (+0.01)
USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
GlobeNewswire - Mon Jan 26, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today that in a new publication in the journal mBio, scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID), Harvard University, and Massachusetts Institute of Technology (MIT) studied genetic changes in the Ebola virus (EBOV) circulating in West Africa and concluded that genomic drift of the EBOV over time may be sufficient to block the action of otherwise potential therapies that target EBOV genetic sequences. The types of potential drugs at risk include monoclonal antibodies and small-interfering RNA (siRNA) which are scheduled to be evaluated during the current outbreak (see below). The USAMRIID press release states that "genetic drift must be considered when developing potential therapeutics, in order to ensure that changes in the Ebola virus over time do not render those treatments ineffective......the USAMRIID team compared the current strain, called EBOV/Mak, with the two previous strains that caused outbreaks in 1976 and 1995 in Zaire (now the Democratic Republic of the Congo). In each comparison, they found more than 600 genetic mutations. Next, the group focused on only the mutations that occurred in the genetic sequences targeted by the experimental therapeutics. Of these, they found 10 new mutations that might interfere with the mechanisms of the sequence-based drugs currently being tested. Three of these mutations appeared during the current West African outbreak." (http://www.usamriid.army.mil/newsroom.htm). HEB: 0.25 (+0.01)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Hemispherx Biopharma Awarded $770,852 by Federal Judge
GlobeNewswire - Thu Jan 15, 7:59AM CST
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"
announced that after prevailing in a federal lawsuit brought against the Company by Cato Capital, the United States District Court for the District of Delaware has ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76. Previously, in September 2014, the Court dismissed all claims brought by Cato against Hemispherx, including counts of breach of contract and fraudulent inducement--completely vindicating the Company of any wrongdoing. HEB: 0.25 (+0.01)
Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
GlobeNewswire - Mon Jan 12, 8:16AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen(R) (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx. HEB: 0.25 (+0.01)
Biotech Weekly: Lessons Learned From Investing In Ebola Stocks
Daniel Ward - at Seeking Alpha - Mon Jan 12, 7:38AM CST
HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36)
Arrowhead Issues Diligence and Valuation Report on Hemispherx Biopharma
GlobeNewswire - Fri Jan 09, 7:38AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announces that Arrowhead BID issued an analyst report on Thursday, January 8, 2015 which can be seen at http://www.abid.co/sites/default/files/HEMISP...8Jan15.pdf. HEB: 0.25 (+0.01)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22)
Hemispherx Biopharma Down 5.3%, Shares Slide into the Red (HEB)
Comtex SmarTrend(R) - Tue Dec 23, 12:41PM CST
Hemispherx Biopharma (AMEX:HEB) is one of today's worst performing penny stocks, down 5.3% to $0.23 on 1.1x average daily volume. Thus far today, Hemispherx Biopharma has traded 847,000 shares, vs. average volume of 747,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's 0.6%) and underperformed the S&P 500 (-5.3% to the S&P's 0.3%) during today's trading.
HEB: 0.25 (+0.01)
Biotech Equities Technical Analysis -- Incyte, ZIOPHARM Oncology, Hemispherx Biopharma, Infinity Pharma, and Orexigen Therapeutics
PR Newswire - Fri Dec 19, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Hemispherx Biopharma Inc. (NYSE MKT: HEB), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 18, 2014, rallied as the Dow Jones Industrial Average finished at 17,778.15, up 2.43% and the NASDAQ Composite closed at 4,748.40, up 2.24%. The S&P 500 finished the session 2.40% higher at 2,061.23. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 813.60, up 2.77%, with the index advancing 8.37% in the previous three months. Register for your complimentary reports on these five stocks at:
OREX: 5.55 (+0.10), ZIOP: 9.64 (-0.35), HEB: 0.25 (+0.01), INCY: 75.94 (+0.28), INFI: 15.13 (+0.55)
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
GlobeNewswire - Tue Dec 16, 7:37AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today further progress on developing Ampligen(R) (rintatolimod) as a potential therapeutic complement to a new molecular class of anti-tumor drugs termed immune checkpoint inhibitors or PD-1 inhibitors (also called Programmed Death inhibitors). PD-1 inhibitors act to unleash the body's own immune system to scavenge/ destroy tumors: remarkable success to date clinically has been reported by Bristol Meyers Squibb (BMS), Merck, Genetech and Novartis on a variety of human tumors including malignant melanoma and metastatic renal cancer with PD inhibitors. In some of these cases, full regulatory approval of commercialization for PD-1 inhibitors has already been received internationally or is expected to be received shortly. Objective tumor regressions are typically seen in approximately 10 to 25% of patients with PD-1 checkpoint inhibitors, such compounds have been generally well-tolerated clinically with a few exceptions noted to date. HEB: 0.25 (+0.01), MRK: 58.81 (-0.07)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), TKMR: 21.45 (-0.22), ABIO: 0.70 (+0.03)
Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research
GlobeNewswire - Tue Dec 09, 8:52AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today that it has received a new research report (dated December 5, 2014) from researchers at Howard University, Washington DC. The report describes a study in which Ampligen(R) (Poly I : Poly C12U) strongly inhibited the Ebola minigenome in the human embryonic kidney cell system. The Ebola minigenome replication system was recently described by the researchers in the Journal of Biological Chemistry (2014) (Role of Protein Phosphatase 1 in Dephosphorylation of Ebola Virus VP30 Protein and Its Targeting for the Inhibition of Viral Transcription; Ilinykh et al. 289(33):22723-22738). In the minigenome replication system, certain genetic information for viral proteins has been deleted from the genomic array to permit safer and more efficient laboratory manipulations. HEB: 0.25 (+0.01)
Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 08, 10:35AM CST
HEB: 0.25 (+0.01), IBIO: 0.90 (+0.36), MNKD: 7.00 (+0.02), ARNA: 4.55 (+0.02)
Biotech industry group supports adding Ebola to Voucher Program Act
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 12:57PM CST
JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
